Skip to content
value.today

G1 Therapeutics, Inc.

Total raised
$80 M
4 rounds on record
Latest round
$50 M
Apr 2016
First round on record
Apr 2013
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of G1 Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2016$50 MNo. 4$50 to $250 million

G1 Therapeutics, Inc.: Raise no. 4, Apr 2016

Investors in this round

21 investors had bought by the notice of Jul 1, 2016: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for G1 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory N. Mossinghoff · Executive Officer
  • Mark A. Velleca · Executive Officer, Director
  • Christy A. Shaffer · Director
  • Frederic N. Eshelman · Director
  • Glenn A. Muir · Director
  • Peter A. Kolchinsky · Director
  • Ron A. Laufer · Director
  • Seth A. Rudnick · Director
  • Timothy N. Sullivan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory Mossinghoff, Chief Business Officer and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Jul 1, 2016. Read the notice at the SEC.

equitySEC
Feb 2015$17 MNo. 3$10 to $50 million

G1 Therapeutics, Inc.: Raise no. 3, Feb 2015

Investors in this round

10 investors had bought by the notice of Feb 12, 2015: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for G1 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $33 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory A. Mossinghoff · Executive Officer
  • Mark A. Velleca · Executive Officer, Director
  • Carol A. Webb · Director
  • Christy A. Shaffer · Director
  • Clay A. Thorp · Director
  • Michael A. Gutch · Director
  • Norman A. Sharpless · Director
  • Ron A. Laufer · Director
  • Seth A. Rudnick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Gregory Mossinghoff, Chief Business Officer. Source: SEC Form D, newest notice filed Feb 12, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$13 MNo. 2$10 to $50 million

G1 Therapeutics, Inc.: Raise no. 2, Oct 2013

Investors in this round

8 investors had bought by the notice of Jun 23, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for G1 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jay K Strum · Executive Officer
  • Mark A. Velleca · Executive Officer, Director
  • Thomas K Laundon · Executive Officer
  • Carol A. Webb · Director
  • Christy A. Shaffer · Director
  • Michael K Gutch · Director
  • Norman A. Sharpless · Director
  • Ron K Laufer · Director
  • Seth K Rudnick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Mark Velleca, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 23, 2014. Read the notice at the SEC.

equitySEC
Apr 2013$1 MNo. 1Under $2 million

G1 Therapeutics, Inc.: Raise no. 1, Apr 2013

Investors in this round

6 investors had bought by the notice of Aug 23, 2013: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for G1 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jay Strum · Executive Officer, Director
  • Thomas K Laundon · Executive Officer
  • Carol Webb · Director
  • Christy Shaffer · Director
  • Clay Thorp · Director
  • Norman Sharpless · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Jay Strum, Ph.D., President. Source: SEC Form D, newest notice filed Aug 23, 2013. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • G1 Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2016).

    SEC Form D · Jul 2016

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2016

That is all the official record says: G1 Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in G1 Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Eshelman Ventures, LLCVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Glenn P. MuirPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2017)SEC Form 3
Jay StrumPersonnot statednot statedHeld preferred stock (Form 3, 2017)SEC Form 3
MedImmune Ventures, Inc.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by G1 Therapeutics, Inc.
NameRoleNamed in
Gregory N. MossinghoffExecutive officerJul 2016
Mark A. VellecaExecutive officerJul 2016
Gregory A. MossinghoffExecutive officerFeb 2015
Jay K StrumExecutive officerJun 2014
Thomas K LaundonExecutive officerJun 2014
Jay StrumExecutive officerOct 2013
Christy A. ShafferDirectorJul 2016
Frederic N. EshelmanDirectorJul 2016
Glenn A. MuirDirectorJul 2016
Mark A. VellecaDirectorJul 2016
Peter A. KolchinskyDirectorJul 2016
Ron A. LauferDirectorJul 2016
Seth A. RudnickDirectorJul 2016
Timothy N. SullivanDirectorJul 2016
Carol A. WebbDirectorFeb 2015
Clay A. ThorpDirectorFeb 2015
Michael A. GutchDirectorFeb 2015
Norman A. SharplessDirectorFeb 2015
Michael K GutchDirectorJun 2014
Ron K LauferDirectorJun 2014
Seth K RudnickDirectorJun 2014
Carol WebbDirectorOct 2013
Christy ShafferDirectorOct 2013
Clay ThorpDirectorOct 2013
Jay StrumDirectorOct 2013
Norman SharplessDirectorOct 2013